Damora Therapeutics (DMRA) Non-Current Assets (2019 - 2026)

Damora Therapeutics has reported Non-Current Assets for 8 years, with the latest figure at $34000.0 in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 92.69% year-over-year to $34000.0; the trailing twelve-month figure through Mar 2026 stood at $1.8 million (down 64.34% YoY), and the FY2025 full-year result was $127000.0, down 56.66% from the prior year.
• Non-Current Assets for Q1 2026 stood at $34000.0, down from $127000.0 in the prior quarter.
• The five-year high for Non-Current Assets was $11.9 million in Q1 2022, with the low at $34000.0 in Q1 2026.
• Historically, Non-Current Assets has averaged $3.9 million across 5 years, with a median of $2.1 million in 2024.
• Annual changes were most pronounced in 2022 — Non-Current Assets decreased 23.33% — and 2026, when it tumbled 92.69%.
• Damora Therapeutics' Non-Current Assets stood at $9.3 million in 2022, then slumped by 84.36% to $1.5 million in 2023, then plunged by 79.83% to $293000.0 in 2024, then sank by 56.66% to $127000.0 in 2025, then tumbled by 73.23% to $34000.0 in 2026.
• The last three Non-Current Assets figures came in at $34000.0 (Q1 2026), $127000.0 (Q4 2025), and $950000.0 (Q3 2025), per Business Quant data.